vargatef

DRUG2 trials

Sponsors

ARCAGY/ GINECO GROUP, Royal Marsden NHS Foundation Trust

Conditions

Adenocarcinoma of LungNSCLC, RecurrentOvarian Cancer

Phase 1

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

WithdrawnNCT03361319

Royal Marsden NHS Foundation TrustAdenocarcinoma of Lung, NSCLC, Recurrent

Start: 2020-07-31End: 2023-07-31Updated: 2020-11-24

Phase 2

Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer

CompletedNCT01583322

ARCAGY/ GINECO GROUPOvarian Cancer

Start: 2012-06-30End: 2016-03-31Updated: 2023-09-06

Related Papers

Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer.

2025-11-24

Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.

2024-12-122 citations

Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.

Journal of Clinical Oncology2024-06-01

Targeting the CD47/TSP-1 axis: A promising strategy for patients with ovarian cancer (OC) that relapses on PARP inhibitors (PARPi).

Journal of Clinical Oncology2024-06-01

46MO What are the predictors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers? Consistent data from two large independent datasets

ESMO Open2024-06-01

Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy

Clinical Cancer Research2024-04-264 citations

CD47 expression in ovarian cancer: Dynamic correlation with lymphocyte and macrophage features as well as thrombospondin-1 (TSP-1) under neoadjuvant chemotherapy.

Journal of Clinical Oncology2023-06-011 citations

Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.

2023-01-2511 citations

1032 Strong association between pathological response to neoadjuvant chemotherapy, TILs and modeled CA125 KELIM in ovarian carcinomas: CHIVA trial, GINECO

2021-10-01

Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer

European Journal of Nuclear Medicine and Molecular Imaging2020-11-2114 citations

Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).

2020-07-2210 citations

CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Clinical Cancer Research2020-03-24120 citations

Modeled CA-125 kinetics during neoadjuvant chemotherapy for predicting the likelihood of optimal interval debulking surgery in ovarian cancer patients: Data from CHIVA trial (a GINECO study).

Journal of Clinical Oncology2019-05-201 citations

Progastrin, a novel ubiquitous cancer blood biomarker for early detection and monitoring.

Journal of Clinical Oncology2019-05-20